Researchers at the University of Edinburgh have advanced a cell therapy approach for advanced liver disease, aiming to repair damaged tissue in patients facing cirrhosis and liver failure. The work centers on using the patient’s own immune cells, described as a potential paradigm shift for outcomes in advanced settings. The reported development frames the therapy as a clinically oriented translational effort, with the objective of improving prognosis when conventional options are limited. The description emphasizes clinical intent—repairing liver tissue—rather than only mechanistic findings. As details on trial design and endpoints are not included in the provided text, the immediate industry takeaway is the continued push to bring immune-cell-based liver repair strategies into patient-focused evaluation.